Apps Ahead For Diabetes: Q&A With DexCom’s Terry Gregg
This article was originally published in The Gray Sheet
Continuous glucose monitor developer DexCom is staking its future on an app-based platform for sensor-insulin pump systems. CEO Terrance Gregg offers an update on the company’s efforts, his thoughts on the space and the growing interest in glucose monitoring by big tech firms like Apple and Google.
You may also be interested in...
Recent activities by three smartphone giants point to a potential future where the phone itself more frequently serves as a monitoring or diagnosing device, in place of external sensors. If the trend rolls on, it could have important implications for the mobile health sector.
Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue
At advisory committee meeting on Acrotech's two peripheral T-cell lymphoma drugs, FDA reviewers suggest they are more willing to seek product withdrawal for failure to conduct studies with due diligence when there are numerous available therapies.
Total ban on background music is unnecessary, agency says in denying KEI’s petition. FDA points to new ‘major statement’ rule and its previous letters objecting to a sponsor’s use of music in ads and says it will continue case by case analysis of ‘all of the elements’ in an ad.